While the reductions in GlcCer and GalCer species in CSF observed following LRRK2 inhibition will require confirmation in a larger clinical study, our data provide support for the continued exploration of GSLs as PD-relevant biomarkers of LRRK2 activity in CSF. The gene discussed is LRRK2; the disease is Parkinson disease.